Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.5
USD
|
+1.35%
|
|
0.00%
|
-22.28%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
331.2
|
277.3
|
84.28
|
38.89
|
32.39
|
25.18
|
-
|
-
|
Enterprise Value (EV)
1 |
293.8
|
179.6
|
17.67
|
-35.54
|
-10.81
|
16.73
|
42.94
|
70.17
|
P/E ratio
|
-
|
-
|
-1.34
x
|
-0.43
x
|
-0.71
x
|
-0.62
x
|
-0.75
x
|
-1.06
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
17.6
x
|
165
x
|
-
|
-
|
-
|
1.81
x
|
EV / Revenue
|
-
|
-
|
3.69
x
|
-151
x
|
-
|
-
|
-
|
5.04
x
|
EV / EBITDA
|
-3.38
x
|
-1.98
x
|
-0.33
x
|
0.64
x
|
-
|
-0.42
x
|
-0.76
x
|
-
|
EV / FCF
|
-
|
-
|
-390,372
x
|
695,180
x
|
291,275
x
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-0%
|
0%
|
0%
|
-
|
-
|
-
|
Price to Book
|
2.82
x
|
3.37
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
4,594
|
5,291
|
5,772
|
14,192
|
16,785
|
16,787
|
-
|
-
|
Reference price
2 |
72.10
|
52.40
|
14.60
|
2.740
|
1.930
|
1.500
|
1.500
|
1.500
|
Announcement Date
|
3/11/20
|
3/23/21
|
3/15/22
|
3/15/23
|
4/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
4.784
|
0.236
|
-
|
-
|
-
|
13.92
|
EBITDA
1 |
-86.99
|
-90.48
|
-53.78
|
-55.39
|
-
|
-40.11
|
-56.76
|
-
|
EBIT
1 |
-89.65
|
-93.93
|
-56.66
|
-57.57
|
-44.67
|
-35.46
|
-43.24
|
-27.35
|
Operating Margin
|
-
|
-
|
-1,184.47%
|
-24,394.92%
|
-
|
-
|
-
|
-196.53%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-60.72
|
-59.93
|
-39.86
|
-41.23
|
-36.74
|
-28.25
|
Net income
1 |
-
|
-
|
-60.72
|
-59.93
|
-39.86
|
-41.23
|
-36.74
|
-28.25
|
Net margin
|
-
|
-
|
-1,269.34%
|
-25,392.8%
|
-
|
-
|
-
|
-202.97%
|
EPS
2 |
-
|
-
|
-10.90
|
-6.310
|
-2.700
|
-2.420
|
-2.010
|
-1.410
|
Free Cash Flow
|
-
|
-
|
-45.26
|
-51.12
|
-37.1
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-945.97%
|
-21,663.14%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/23/21
|
3/15/22
|
3/15/23
|
4/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
4.784
|
-
|
0.236
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-9.284
|
-9.764
|
-10.27
|
-
|
EBIT
1 |
-14.83
|
-9.898
|
-18.27
|
-12.26
|
-13.13
|
-13.92
|
-10.65
|
-11.96
|
-14.93
|
-7.677
|
-9.382
|
-9.851
|
-10.34
|
-10.86
|
Operating Margin
|
-
|
-206.9%
|
-
|
-5,194.07%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-16.45
|
-10.69
|
-18.92
|
-13.14
|
-13.71
|
-14.17
|
-10.86
|
-12.2
|
-15.29
|
-4.339
|
-9.576
|
-10.05
|
-10.54
|
-11.06
|
Net income
1 |
-16.45
|
-10.69
|
-18.92
|
-13.14
|
-13.71
|
-14.17
|
-10.86
|
-12.2
|
-15.29
|
-4.339
|
-9.576
|
-10.05
|
-10.54
|
-11.06
|
Net margin
|
-
|
-223.52%
|
-
|
-5,566.53%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-3.000
|
-1.800
|
-2.800
|
-1.900
|
-1.360
|
-1.000
|
-0.7600
|
-0.8500
|
-1.050
|
-0.2800
|
-0.5700
|
-0.5900
|
-0.6200
|
-0.6400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/15/22
|
5/10/22
|
8/12/22
|
11/8/22
|
3/15/23
|
5/9/23
|
8/8/23
|
11/13/23
|
4/15/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
17.8
|
45
|
Net Cash position
1 |
37.5
|
97.7
|
66.6
|
74.4
|
43.2
|
8.45
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.3128
x
|
-
|
Free Cash Flow
|
-
|
-
|
-45.3
|
-51.1
|
-37.1
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-58.4%
|
-92.3%
|
-85.3%
|
-94.8%
|
-94.4%
|
-314%
|
-580%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
25.60
|
15.60
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
1.59
|
0.65
|
0.2
|
0.1
|
0.01
|
0.65
|
0.65
|
0.65
|
Capex / Sales
|
-
|
-
|
4.08%
|
40.68%
|
-
|
-
|
-
|
4.67%
|
Announcement Date
|
3/11/20
|
3/23/21
|
3/15/22
|
3/15/23
|
4/15/24
|
-
|
-
|
-
|
Average target price
6
USD Spread / Average Target +300.00% Consensus |
1st Jan change
|
Capi.
|
---|
| -22.28% | 25.18M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|